Phase I Open-Label Study on Pharmacokinetics of IRL757 in Elderly Patients with Apathy in Neurodegenerative Disorders

The primary objective of this study is to evaluate the **pharmacokinetics** of single ascending oral doses of IRL757 in healthy elderly volunteers. This is clinically relevant as it aims to understand the absorption, distribution, metabolism, and excretion of the drug, which is crucial for determining appropriate dosing regimens. The study focuses on addressing **apathy in neurodegenerative disorders**, a condition that significantly impacts the quality of life in affected individuals. Understanding the pharmacokinetics in the target population is essential for optimizing therapeutic strategies and ensuring safety and efficacy in clinical use.

The clinical trial focuses on **apathy in neurodegenerative disorders** and includes both male and female participants. The study population encompasses adults aged 18 to 64 years, representing a non-vulnerable group. The sponsor has not provided information regarding the total number of participants. The selection criteria for the trial population have not been disclosed, and there are no specific lifestyle considerations such as diet or physical activity mentioned. Key inclusion or exclusion criteria are not specified in the available data.

The clinical trial is a **single-centre, open-label, phase I** study designed to evaluate the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers. The trial focuses on understanding the drug's behavior in the body, specifically targeting **apathy in neurodegenerative disorders**. The study is scheduled to commence recruitment on September 2, 2024, and is expected to conclude by December 31, 2024. Participants will be involved in the trial for a duration that aligns with the study's timeline, with specific visit schedules to be determined based on the dosing regimen.

The trial design does not incorporate randomization or blinding, as it is an open-label study. Participants will undergo an initial **screening visit** to assess eligibility based on predefined criteria. This visit will include a comprehensive review of medical history, physical examination, and necessary laboratory tests. Following successful screening, participants will be enrolled and scheduled for subsequent study visits, which will involve the administration of the investigational product and monitoring of pharmacokinetic parameters.

Throughout the trial, participants will attend **follow-up visits** to collect data on drug absorption, distribution, metabolism, and excretion. These visits are crucial for ensuring participant safety and for gathering data to meet the study's objectives. The **end-of-study visit** will mark the completion of the participant's involvement, during which final assessments will be conducted to evaluate the overall impact of the investigational product.

Participant involvement is expected to last until the end of the study, barring any conditions that may necessitate early termination. Such conditions include adverse events, withdrawal of consent, or any other factors that compromise participant safety or data integrity. The study is conducted in accordance with ethical guidelines and regulatory requirements to ensure the safety and well-being of all participants.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

The clinical trial is designed to assess efficacy through a structured evaluation process. As the trial is in Phase 3, it aims to confirm the effectiveness of the intervention in a larger patient population. The trial is scheduled to commence recruitment on September 2, 2024, with an estimated completion date of December 31, 2024. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical assessments in Phase 3 trials may include symptom improvement scores, biomarker levels, or disease remission rates. These parameters are usually measured at predetermined timepoints using validated scales, laboratory tests, or patient-reported outcomes. The data collected will be analyzed to determine the intervention's efficacy, contributing to the overall evaluation of its therapeutic potential.